Conditions: Neovascular Age-related Macular Degeneration
Keywords: Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 107
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).

Detailed description:
This is a randomized, double-masked, placebo-controlled, dose-ranging, multicenter study to assess the efficacy and safety of AKST4290 administered orally at 400 mg b.i.d. or 800 mg b.i.d. in combination with intravitreal aflibercept injections (IAI), in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD) who are naïve to treatment with anti-vascular endothelial growth factor (anti-VEGF) medications in the study eye. Subjects will be treated with AKST4290 800 mg daily, 1600 mg daily, or placebo for a total of 36 weeks.

Arms:
arm 1: Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment arm 2: Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment arm 3: Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment

Interventions: intervention 1: AKST4290 intervention 2: Placebo intervention 3: Aflibercept
Intervention descriptions: intervention 1: Oral AKST4290 intervention 2: Oral placebo intervention 3: Aflibercept intravitreal injection

Protocol document:
Prot_000.pdf: 



















































































































































SAP_001.pdf: 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0
Protocol Version: 3.0
Confidential
Page 2 of 20




Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 4 of 20 
3. TABLE OF CONTENTS 
1.
Signature Page .................................................................................................................... 2 
2.
Revision History ................................................................................................................... 3 
2.1. 
Summary of Changes ................................................................................................... 3 
3.
Table of Contents ................................................................................................................ 4 
4.
Abbreviations ....................................................................................................................... 6 
5.
Definitions ............................................................................................................................ 6 
6.
Protocol Summary ............................................................................................................... 6 
7.
Study Objectives .................................................................................................................. 7 
7.1. 
Primary Objective ......................................................................................................... 7 
7.2. 
Secondary Objectives ................................................................................................... 7 
7.3. 
Exploratory Objectives .................................................................................................. 7 
8.
Study Endpoints .................................................................................................................. 8 
8.1. 
Primary Endpoint .......................................................................................................... 8 
8.2. 
Secondary Endpoints .................................................................................................... 8 
8.3. 
Exploratory Endpoints ................................................................................................... 8 
9.
Sample Size ........................................................................................................................ 8 
10. General Considerations for Data Analysis............................................................................ 8 
10.1. General Principles ........................................................................................................ 8 
10.2. Analysis Populations ..................................................................................................... 9 
10.2.1. Intent-to-Treat ........................................................................................................ 9 
10.2.2. Safety Evaluable .................................................................................................... 9 
10.2.3. Per Protocol ........................................................................................................... 9 
10.3. Data Transformations and Derivations .......................................................................... 9 
10.4. Missing Data and Imputation ........................................................................................ 9 
10.5. Sub-Groups ................................................................................................................ 10 
10.6. Covariates .................................................................................................................. 10 
10.7. Multicenter Studies ..................................................................................................... 10 
10.8. Significance Level ....................................................................................................... 10 
10.9. Multiple Comparisons ................................................................................................. 10 
10.10. Timing of Analyses ..................................................................................................... 10 
10.11. Interim Analyses ......................................................................................................... 10 
10.12. Software ..................................................................................................................... 11 
10.13. Reporting Conventions ............................................................................................... 11 
10.13.1. General................................................................................................................ 11 
10.13.2. Tables ................................................................................................................. 12 
10.13.3. Listings ................................................................................................................ 12 
11. Summary of Study Population............................................................................................ 12 
11.1. Subject Disposition ..................................................................................................... 12 
11.2. Demographic and Other Baseline Characteristics ....................................................... 12 
11.3. Medical History ........................................................................................................... 13 
11.4. Prior and Concomitant Medications ............................................................................ 13 
11.5. Treatment Compliance ............................................................................................... 13 
11.6. Protocol Deviations ..................................................................................................... 13 
12. Safety Analyses ................................................................................................................. 13 
12.1. Extent of exposure ...................................................................................................... 13 
12.2. Adverse Events .......................................................................................................... 13 
12.3. Laboratory Evaluations ............................................................................................... 14 
12.4. Vital Signs .................................................................................................................. 14 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 5 of 20 
12.5. Physical Examination .................................................................................................. 14 
12.6. 12-lead ECG ............................................................................................................... 14 
12.7. Pregnancies ............................................................................................................... 15 
13. Efficacy Analyses ............................................................................................................... 15 
13.1. Primary Efficacy Analysis............................................................................................ 15 
13.1.1. Additional Analyses of the Primary Endpoint ....................................................... 15 
13.2. Secondary Efficacy Analyses ...................................................................................... 16 
13.2.1. BCVA Categorical Change .................................................................................. 16 
13.2.2. Time to First PRN Injection/First Visit Where PRN Injection Criteria are Met ....... 16 
13.2.3. Median Number of Injections Received per Week ............................................... 16 
13.2.4. Mean Change from Baseline in CST and Compared to Control at Week 12 ........ 17 
13.2.5. Mean AUC Change from Baseline in BCVA ETDRS Letters Read and CST ........ 17 
13.3. Exploratory Efficacy Analyses ..................................................................................... 17 
13.4. Sensitivity Efficacy Analyses ....................................................................................... 18 
13.5. Biomarker and Aqueous Humor Analyses .................................................................. 18 
13.6. Pharmacogenomic Analyses ...................................................................................... 18 
14. Pharmacokinetic Analyses ................................................................................................. 18 
15. Changes in the Conduct of the Study or Planned Analyses ............................................... 19 
16. List of Tables, Listings, and Figures ................................................................................... 20 
16.1. Tables......................................................................................................................... 20 
16.2. Listings ....................................................................................................................... 20 
16.3. Figures ....................................................................................................................... 20 
 
 
 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 6 of 20 
4. ABBREVIATIONS 
AE 
 
adverse event 
ANOVA 
analysis of variance 
ATC 
 
Anatomical Therapeutic Chemical 
BCVA  
best corrected visual acuity 
BMI 
 
body mass index 
CI 
 
confidence interval 
CNV 
 
choroidal neovascularization 
CRT 
 
central retinal thickness 
CST 
 
Central Subfield Thickness 
ECG 
 
electrocardiogram 
eCRF  
electronic case report form 
EDC 
 
electronic data capture 
EDTRS 
Early Treatment Diabetic Retinopathy Study 
EOT 
 
End of Treatment 
FA 
 
fluorescein angiography 
FAF 
 
fundus autofluorescence 
FP 
 
fundus photography 
IAI 
 
Intravitreal Aflibercept Injection 
iReST  
International Reading Speed Texts 
IRF 
 
intraretinal fluid 
ITT 
 
intent to treat 
LLVA  
low-luminance visual acuity 
MedDRA 
Medical Dictionary for Regulatory Activities 
mERG  
multifocal electroretinogram 
MMRM 
mixed effects model for repeated measures 
nAMD  
neovascular age-related macular degeneration 
NEI-VFQ-39 National Eye Institute  Visual Functioning Questionnaire-39 
PK 
 
pharmacokinetic 
PP 
 
per-protocol 
RPED  
retinal pigment epithelial detachment 
SAP 
 
statistical analysis plan 
SD-OCT 
Spectral Domain Optical Coherence Tomography 
SRF 
 
subretinal fluid 
ULN 
 
upper limit of normal 
WHO  
World Health Organization 
5. DEFINITIONS 
Incidence (of an event, among a group)  proportion of subjects experiencing at least one event of the 
specified type. 
Adverse event surveillance period (for a subject)  time from start of study treatment until trial 
completion. 
6. PROTOCOL SUMMARY 
This is a Phase 2, double-masked, placebo-controlled, dose-ranging, multicenter study to assess the 
efficacy and safety of AKST4290 administered orally at 400 mg twice per day (b.i.d.) (total daily dosage 
of 800 mg) (Arm 1) or 800 mg b.i.d. (total daily dosage of 1600 mg) (Arm 2) in combination with 
intravitreal aflibercept injections (IAI), in subjects with newly diagnosed neovascular age-related 
macular degeneration (nAMD) who are naïve to treatment with anti-vascular endothelial growth factor 
(anti-VEGF) medications in the study eye. Subjects will be treated with AKST4290 800 mg daily (Arm 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 7 of 20 
1), 1600 mg daily (Arm 2), or placebo (Arm 3) for a total of 36 weeks. All subjects will receive 3 loading 
doses of IAI, with the initial dose administered on Day 1 (Visit 2) followed by 2 additional doses every 4 
weeks (q4w) at Visits 3 and 4. Starting at 12 weeks (Visit 5), subjects in Arms 1 and 2 will be evaluated 
for IAI on a pro re nata (PRN) basis per strict injection criteria q4w. Subjects in Arms 1 and 2 who do 
not meet PRN injection criteria will receive a sham injection for masking purposes. Starting at 12 weeks 
(Visit 5), subjects in Arm 3 will receive IAI every 8 weeks (q8w) (at 16, 24, and 32 weeks [Visits 6, 8, 
and 10]) with PRN IAI evaluations conducted at every visit for masking purposes. In Arm 3, at 12, 20, 
28, and 36 weeks (Visits 5, 7, 9, and 11) subjects that do not meet PRN injection criteria will receive 
sham injections for masking purposes. All subjects that meet PRN injection criteria will be administered 
IAI. For masking purposes, all PRN IAI assessments will be performed by a masked investigator and 
IAI or sham injections will be performed by an unmasked injector. Treatment will be discontinued after 
Week 36 in all study arms, and subjects will then be followed for an additional 4 weeks. 
 
Approximately 120 subjects will be enrolled with the intent of obtaining approximately 100 evaluable 
subjects. Subjects will be randomized to active treatment in Arm 1 (approximately 33 evaluable 
subjects) or Arm 2 (approximately 33 evaluable subjects), or to placebo in Arm 3 (approximately 33 
evaluable subjects). All subjects will be masked as to their dose of AKST4290 by using a combination 
of active or placebo tablets. All subjects will orally self-administer AKST4290 or placebo b.i.d. The 
randomization schema is 1:1:1, stratified for study site and Early Treatment Diabetic Retinopathy Study 
(EDTRS) best-corrected visual acuity (BCVA) category for letters read at screening (< 55 vs.  55).  
7. STUDY OBJECTIVES 
7.1. 
PRIMARY OBJECTIVE 
The primary objective of the study is to evaluate the potential therapeutic effects of a 36-week, b.i.d. 
oral dosing regimen of AKST4290, with loading doses of IAI, by assessing the improvement in BCVA 
using ETDRS method. 
7.2. 
SECONDARY OBJECTIVES 
The secondary objectives include the time to PRN injection (Arms 1 and 2 only), time to the first visit 
where PRN injection criteria are met, median number of injections received beginning at Baseline and 
Week 12, proportion of subjects with a mean change in BCVA letter score of 0-5, 6-10, 11-15, > 15 
letters lost or gained, mean change in central subfield thickness (CST) on spectral-domain-optical 
coherence tomography (SD-OCT) compared to control through Week 12, mean AUC change in BCVA 
and CST from Baseline to Week 36, and overall safety. Additionally, a secondary objective will be the 
comparison of the mean change from baseline in BCVA in Arms 1 and 2 to Arm 3 (control) through 
Week 12 as well as mean change from Week 12 in BCVA per the ETDRS testing method. 
7.3. 
EXPLORATORY OBJECTIVES 
Exploratory objectives will include the evaluations of changes in visual field (as available), low-
luminance visual acuity (LLVA), and reading speed. Evaluations of multifocal electroretinogram 
(mERG) will also be performed at select sites, as available. Morphologic changes in central retinal 
thickness (CRT), subretinal fluid (SRF), intraretinal fluid (IRF), retinal pigment epithelial detachment 
(RPED) height, and cube volume will be evaluated by SD-OCT, and total CNV area will be evaluated by 
fluorescein angiography (FA). Biomarker, PK, and pharmacogenomic evaluations will be conducted on 
blood and plasma samples. Dose response will be investigated by assessing the mean change in 
BCVA and the number of injections in Arms 1-3 by study visit. Changes in the National Eye Institute-
Visual Functioning Questionnaire-39 (NEI-VFQ-39) will also be assessed. Optional aqueous humor 
testing for markers of inflammation will be conducted in select subjects. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 8 of 20 
8. STUDY ENDPOINTS 
8.1. 
PRIMARY ENDPOINT 
Mean change from baseline in BCVA per the ETDRS testing method. 
8.2. 
SECONDARY ENDPOINTS 
1.
Time to PRN injection (Arms 1 and 2 only). 
2.
Time to first visit where PRN injection criteria are met. 
3.
Median number of injections received beginning at Baseline and Week 12. 
4.
Proportion of subjects with BCVA change of 0-5, 6-10, 11-15, > 15 letters lost or gained. 
5.
Mean change in CST compared with control through Week 12. 
6.
Mean change in BCVA per the ETDRS testing method compared with control through Week 12. 
7.
Mean change from Week 12 in BCVA per the ETDRS testing method. 
8.
Mean AUC change in BCVA and CST from Baseline to Week 36. 
9.
Safety as assessed by incidence and intensity of AEs. 
8.3. 
EXPLORATORY ENDPOINTS 
1.
Changes in visual field (as available), LLVA, and reading speed. 
2.
Evaluation of mERG at select sites, as available. 
3.
Changes in CRT, SRF, IRF, RPED height and cube volume as measured by SD-OCT, and total 
CNV area as measured by FA. 
4.
Biomarker, PK, and pharmacogenomic assessments. 
5.
Dose response as assessed by mean change in BCVA and mean number of injections in by study 
visit. 
6.
Change in NEI-VFQ-39 score by study visit. 
7.
Optional aqueous humor testing for markers of inflammation will be conducted in select subjects. 
9. SAMPLE SIZE 
The primary efficacy analysis objective is to observe an improvement in the mean number of letters 
read from baseline to Week 36 in the AKST4290 treatment groups of at least seven letters. A sample 
size of 33 subjects achieves approximately 85% power to detect a difference of -7.0 letters between the 
null hypothesis mean of 0.0 and the alternative hypothesis mean of 7.0 letter improvement, with an 
estimated standard deviation of 13 and with a significance level (alpha) of 0.025 using a one-tailed one-
sample t-test. The combined power of testing each AKST4290 treatment group separately as described 
in Section 10.9 is approximately 72%. 
To ensure a sufficient number of subjects are enrolled to effectively assess the mean change in letters 
read within each AKST4290 group and within the two AKST4290 groups combined, the total sample 
size for this study will be 100 evaluable subjects (i.e., approximately 33 subjects in each individual 
treatment group).  
10. GENERAL CONSIDERATIONS FOR DATA ANALYSIS 
10.1. 
GENERAL PRINCIPLES 
All summary statistics will be descriptive unless noted otherwise. Descriptive summaries will include 
mean, standard deviation, median, quartiles and range for continuous variables and counts and 
percentages for categorical variables. Two-sided 95% confidence intervals (CIs) will be provided for the 
means and percentages as needed. For key outcome measures, the difference between the treatment 
arms along with 95% CI of the difference will be computed. 
The assumptions for any planned parametric testing will be assessed for appropriateness. If any are 
violated and inhibit the interpretation of the results, appropriate data transformations or non-parametric 
analyses will be performed in addition to other planned sensitivity analyses to support the interpretation 
of the treatment effect. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 9 of 20 
The primary analysis will evaluate within-group tests for each of the AKST4290 treatment arms (Arms 1 
and 2) separately; as a secondary analysis, each of the AKST4290 groups and the pooled AKST4290 
treatment arms will be compared to the control arm (Arm 3) for data collected through Week 12. All 
study population, safety, and efficacy tabulations will include summaries of each of the three treatment 
arms and a summary for the combined AKST4290 arms. 
Subjects will be analyzed in the treatment group assigned at randomization for the intent-to-treat (ITT) 
and per protocol (PP) data sets (see definitions below). For the Safety Evaluable data set, subjects will 
be grouped according to actual treatment received. 
 
10.2. 
ANALYSIS POPULATIONS 
10.2.1. 
Intent-to-Treat 
Intent-to-Treat (ITT) set will include all randomized subjects. 
10.2.2. 
Safety Evaluable 
Safety Evaluable set (Safety Population) will include all randomized subjects who receive at least one 
dose of the study agent (placebo or AKST4290). 
10.2.3. 
Per Protocol 
Per Protocol (PP) set is a subset of ITT subjects (who receive at least one dose of the study agent) with 
sufficient compliance to the protocol. The following are grounds for exclusion from the PP population: 
1.
Deviation of inclusion/exclusion criteria 
2.
Intake of any prohibited medications listed in Protocol Sections 17.2.1 and 17.2.2 during the study 
period. 
3.
Any other major protocol deviation deemed by the Sponsor to warrant exclusion from the PP set 
The inclusion or exclusion of ITT population subjects to PP population will be finalized before unblinding 
the study. 
10.3. 
DATA TRANSFORMATIONS AND DERIVATIONS 
Values will be presented for all scheduled study visits according to the nominal visit obtained from the 
eCRF. Visit windows are defined in Section 15 (Schedule of Events) of the study protocol. Each visit 
after Day 1 is associated with a target visit day and allows for a ±3 day window for visit completion 
around the target day. If an unscheduled visit falls in a visit window with an existing nominal visit 
assessment, the nominal assessment will be used for summary presentation. If no nominal visit 
assessment exists for a visit window with unscheduled visit(s), then the unscheduled visit within the 
visit window and closest to the target day will be used. If multiple nominal assessments are collected 
within the same visit, the nominal visit closest to the target day will be used for summary presentation. 
Based on these rules, if two visits are equidistant from the target day, the later of the two will be used. 
Data collected at unscheduled visits will be considered when endpoint derivations potentially include 
multiple visits (e.g., determination of baseline value, determination of worst post-baseline value, etc.). 
Subjects that terminate early from the study will have their Week 36/end of treatment (EOT) visit 
mapped and summarized with the next scheduled nominal visit, according to the schedule of events, 
based on the last visit completed per protocol.  
10.4. 
MISSING DATA AND IMPUTATION 
The analysis of the primary endpoint will be based on a mixed effects model for repeated measures 
(MMRM) that uses a likelihood-based estimation method assuming data to be missing at random to 
account subjects who dropout prior to Week 36. The Kenward and Roger method will be used to 
calculate the denominator degrees of freedom for the test of fixed effects. The MMRM model used to 
compare the AKST4290 treatment groups to control through Week 12 will include similar methods for 
accounting for missing data. 
For the secondary responder endpoints (e.g., subjects with  15 letters gained at Week 12 or Week 
36), subjects missing the Week 12 or Week 36 evaluation will be considered as having not achieved 
the success criterion of interest. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 10 of 20 
10.5. 
SUB-GROUPS 
Subgroups will be defined for the following: 
 
BCVA randomization stratification level: <55 vs  55 letters read at screening 
 
PRN injection criteria on study: subjects who never meet the criteria for PRN IAIs vs subjects 
who meet the PRN injection criteria at least once 
 
The primary endpoint analysis will be repeated separately for the BCVA randomization stratification 
levels. Select efficacy endpoints will be defined for the PRN IAI subsets as described in Section 13.4. 
10.6. 
COVARIATES 
The MMRM models to assess the within-group change from baseline to Week 36 and to compare 
treatment groups through Week 12 for the primary efficacy analysis will include a covariate adjustment 
for the baseline number of letters read. The MMRM used to analyze any secondary or exploratory 
efficacy analysis will include a covariate for the baseline value of the parameter of interest.  
10.7. 
MULTICENTER STUDIES 
This is a multicenter study and efficacy data collected from all study sites will be pooled for data 
analysis. The effect of study site on the primary endpoint will be explored as discussed in Section 13.3. 
The effect of study site on other efficacy analysis results may be explored post-hoc, as needed.  
10.8. 
SIGNIFICANCE LEVEL 
The primary analysis utilizes a one-sample test with one-sided significance level 2.5%. 
All other statistical tests and confidence intervals will be two sided (where relevant) and have 
significance level of 5%. 
10.9. 
MULTIPLE COMPARISONS 
The primary analysis will be performed separately for each of the two AKST4290 treatment arms (Arms 
1 and 2) as within-group tests for the change from baseline to Week 36 in BCVA letters read. To 
account for multiple within-group comparisons, Arm 1 (400 mg b.i.d.) will be evaluated first at the one-
sided 2.5% level of significance. If the null hypothesis is rejected, the test will be carried out for Arm 2 
(800 mg b.i.d.). Analysis of secondary endpoints will not be adjusted for multiple endpoint or treatment 
comparisons and will be evaluated based on a two-sided significance level of 5%. This study is 
exploratory in nature and analysis of secondary endpoints in a potential subsequent pivotal study will 
include appropriate methods for adjusting for multiple comparisons.  
10.10. 
TIMING OF ANALYSES 
Safety monitoring will be conducted on an ongoing basis, albeit not by means of statistical 
comparisons, unless the Safety Evaluation Meeting is convened and so decides. 
An interim analysis of efficacy will be performed (see Section 10.11). 
The final analysis will be performed when the enrollment is completed, all the subjects are either 
completed or discontinued, and the database is locked. However, statistical programming for the final 
analysis based on blinded (mock) data will commence before database lock. 
10.11. 
INTERIM ANALYSES 
Safety will be monitored on an ongoing basis. If a Safety Evaluation Meeting is triggered (see Section 
8.5 in Protocol), an ad hoc interim safety analysis will be performed. If such an ad hoc safety interim 
analysis is conducted, the treatment assignment will remain masked, unless aggregate unmasking is 
deemed necessary by the Sponsor for safety evaluation. 
An interim analysis of primary and key secondary and exploratory efficacy endpoint data is planned to 
be performed in May 2021, with all available data collected up to an appropriate prior data cut date 
included. Select safety data will be provided as well. Results of the interim analysis will be utilized to 
assist in making decisions for more advanced studies on subjects with nAMD (e.g., a Phase 3 
program), and to assess further clinical development of AKST4290 in other indications. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 11 of 20 
Analysis of the efficacy endpoints described in Section 13 will be performed in a similar manner for the 
interim analysis. Endpoints collected over time will be summarized at select time points where 
scheduled for evaluation up to the end of study, Week 40, in addition to the primary analysis time point 
at the end of treatment, Week 36.  
Tabulated results of the efficacy and safety data will be prepared by treatment group using blinded 
study data. The unblinded statistician will have access to the unblinded subject treatment assignments 
and will run the tabulated results utilizing the unblinded assignments for the interim analysis. For the 
purposes of the interim analysis, the unblinded statistician will prepare an assessment of each 
endpoint, to include relevant statistics for the parameters of interest, defined by Alkahest as required for 
the interim analysis. In addition to tabulated summaries, subject level data will be reported for the 
primary endpoint to support review of the assessment provided; subject identifiers will be randomly 
sorted and then excluded from presentation in the output. The unblinded statistician will not be involved 
in any ongoing site monitoring, data management, or data handling decision making activities following 
the interim analysis data review up through final database lock. Among specific endpoints for inclusion 
in the interim analysis are the following: 
 
Mean change from baseline in BCVA ETDRS letters read by post-baseline visit 
 
Comparison of BCVA change from baseline between each active arm (or pooled) and control for 
data collected through Week 12 
 
Mean change from baseline in LLVA and Reading Speed by post-baseline visit 
 
Mean change from baseline in Visual Field (Mean Deviation and Pattern Standard Deviation) 
and mERG (Central Rings 1-5) by post-baseline visit 
 
Mean change from baseline in NEI-VFQ-39 sub-scales and composite score by post-baseline 
visit 
 
Area under the curve (AUC) for mean change from baseline in BCVA and CST for specific study 
visit intervals 
 
Time (weeks) to first PRN IAI (Arms 1 and 2 only) 
 
Time (weeks) to first date where PRN injection criteria is met on or after Week 12 
 
Mean number of injections received (scheduled or PRN) per week beginning at Baseline and 
Week 12 through the end of treatment 
 
Liver function tests upper limit of normal (ULN) categories  
 
Adverse events (AEs) occurring in  5% of subjects in either AKST4290 treatment group (Arm 1 
or Arm 2) 
No adjustments to the current protocol are planned as a result of the interim analysis. Therefore, the 
overall type 1 error (alpha) in the in the final analysis will be maintained at 0.025, one sided, for the 
primary endpoint. 
10.12. 
SOFTWARE 
Data analyses will be performed with SAS® version 9.4. 
10.13. 
REPORTING CONVENTIONS 
10.13.1. 
General 
Non-zero percentages will be rounded to one decimal place. Rounding conventions for presentation of 
summary statistics will be based on the precision of the variable of summarization, as it is collected in 
its rawest form (i.e., on the eCRF or as provided within an external file) and are outlined as follows: 
 
The mean and median will be rounded to one more decimal place than the precision of the 
variable of summarization; 
 
Measures of variability (e.g., SD, SE) will be rounded to two more decimal places than the 
precision of the variable of summarization; and 
 
Minimum and maximum values will be presented using the same precision as the variable of 
summarization. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 12 of 20 
Other statistics (e.g., CIs) will be presented using the same general rules outlined above, or assessed 
for the most appropriate presentation based on the underlying data.  P-values will be presented with 
four decimal places and values less than 0.0001 will be presented as <0.0001. 
 
For all fitted statistical models, generally: 
1.
Goodness-of-fit will be examined;  
2.
Results will be displayed in a table of parameters containing at least the parameter estimate, 
standard error of the estimate, and the p-value of a test of null hypothesis of whether the parameter 
is zero 
10.13.2. 
Tables 
Tables will represent summaries and results of other analyses. All summary tables will be structured 
with a column for each treatment group, unless treatment group is clearly irrelevant for the summary 
(e.g., reasons for screening failures), as well as a column for the combined AKST4290 treatment 
groups. Tables summarizing subject disposition, demographics, and other baseline characteristics will 
also include a column for all treatment groups combined. All summary tables be annotated with the 
analysis population and total population size relevant to that table. Confidence intervals and 
corresponding p-values are reported within (or in the captions of) relevant summary tables.  
10.13.3. 
Listings 
Listings will generally present the data as it appears on the eCRFs without any further grouping or 
pooling as used in the analyses. 
subject
subject in one row. Any 
subject 
subject per visit. Otherwise, different results of one subject may be 
organized to separate rows in some other way (e.g., one medical history element per row). All listings 
include the subject ID and treatment group. 
11. SUMMARY OF STUDY POPULATION 
ITT population will be used for all of the following analyses and tabulations, except for the summary of 
screening failures. 
11.1. 
SUBJECT DISPOSITION 
Subject disposition will be presented for all subjects. Numbers of subjects randomized, complete or 
discontinue from the study, and reasons for study discontinuation will be summarized. Subject 
disposition by study center will also be presented. Number and reasons of screening failures are also 
summarized with descriptive statistics. 
11.2. 
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS 
Demographic variables include age, sex, ethnicity, race, and gender. Baseline characteristics include 
height, weight, body mass index (BMI), study eye, study eye color, and time since nAMD diagnosis 
(days). Body mass index will be calculated as: weight (kg) / [height (cm) / 100]2. Time since nAMD 
(days) is calculated as the date of informed consent  date of nAMD diagnosis. Each of these variables 
will also be summarized with descriptive statistics.  
Time (days) since nAMD diagnosis will be computed for partial nAMD diagnosis dates based on the 
following rules: 
 
Day missing but month and year present: The difference in months between the nAMD 
diagnosis date and informed consent date will be calculated based on the available date entries, 
and then multiplied by 30.4 (rounded to the nearest whole number): {[(year of informed consent 
 year of nAMD diagnosis) x 12] + (the month of informed consent  the month of nAMD 
diagnosis)} x 30.4. 
 
Day and month missing but year present: The difference in years between nAMD diagnosis date 
and informed consent date will be calculated based on the available date entries, and then 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 13 of 20 
multiplied by 365.25 (rounded to the nearest whole number: (year of informed consent  year of 
nAMD diagnosis) x 365.25. 
11.3. 
MEDICAL HISTORY 
Medical history elements will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
version 23.0. Incidence of each preferred term will be reported by treatment group. 
11.4. 
PRIOR AND CONCOMITANT MEDICATIONS 
Prior and concomitant medications will be coded with the World Health Organization (WHO) drug 
dictionary version Global B3 September 2018. Prior and concomitant medications will be summarized 
with descriptive statistics by drug Anatomical Therapeutic Chemical (ATC) Classification System (level 
one) and generic name. 
11.5. 
TREATMENT COMPLIANCE 
Treatment compliance is assessed by the number of tablets dispensed to and returned by the subject, 
expressed as a percentage of the intended intake during the study period. The number and 
 compliant within each treatment group 
will be summarized. 
11.6. 
PROTOCOL DEVIATIONS 
Subject-specific protocol deviations will be summarized by category, importance (minor, major) and 
treatment group. 
12. SAFETY ANALYSES 
The Safety Analysis Set will be used for all analyses and tables of safety data. 
12.1. 
EXTENT OF EXPOSURE 
Extent of exposure to study treatment will be summarized by treatment group. The duration of exposure 
will be presented in days and calculated as the date of last dose of study drug minus the date of first 
dose of study drug, plus one. Total number of IAIs (PRN and scheduled), number of PRN IAIs, and 
number of sham injections per subject will also be presented. Duration of exposure, total number of 
IAIs, PRN IAIs, and sham injections will be summarized using descriptive statistics. 
12.2. 
ADVERSE EVENTS 
Treatment-emergent adverse events (TEAEs) are defined as those AEs with onset after the first dose 
of study drug or existing events that worsened after the first dose during the study. Treatment-emergent 
AEs will be summarized by treatment group. Events reported with a partial onset date (e.g., month and 
year are reported but the day is missing) will be considered to be treatment-emergent if it cannot be 
confirmed that the event onset was prior to the first dose of study drug based on the available date 
entries. 
Verbatim terms on case report forms will be mapped to preferred terms and system organ classes 
using the Medical Dictionary for Regulatory Activities (MedDRA). 
Summaries that are displayed by system organ class and preferred terms will be ordered by 
descending incidence of system organ class and preferred term within each system organ class. 
Summaries displayed by preferred term only will be ordered by descending incidence of preferred term. 
Summaries of the following types will be presented: 
 
Overall summary of number of unique TEAEs and treatment-emergent serious adverse events 
(SAEs) and subject incidence of TEAEs meeting various criteria 
 
Subject incidence of TEAEs by MedDRA system organ class and preferred term 
 
TEAEs occurring in  5% of subjects in either AKST4290 treatment group (Arm 1 or Arm 2) 
 
Subject incidence of TEAEs by severity grade, MedDRA system organ class, and preferred term 
 
Subject incidence of TEAEs by relationship to study drug, MedDRA system organ class, and 
preferred term 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 14 of 20 
 
Subject incidence of severe TEAEs related to study drug by MedDRA system organ class and 
preferred term 
 
Subject incidence of injection-related TEAEs by MedDRA system organ class and preferred 
term 
 
Subject incidence of SAEs by MedDRA system organ class and preferred term 
 
Subject incidence of TEAEs of special interest by MedDRA system organ class and preferred 
term 
 
At each level of summarization (e.g., any AE, system organ class, and preferred term), subjects 
experiencing more than one TEAE will be counted only once. In the summary of TEAEs by severity 
grade, subjects will be counted once at the highest severity reported at each level of summarization; in 
the summary of TEAEs by relationship, subjects will be counted once at the closest relationship to 
Unrelated
 
Adverse event data will be presented in data listings by subject, treatment group, and event. Serious 
AEs, AEs leading to discontinuation of the study drug, injection related AEs, and AEs of special interest 
will be presented in separate data listings. 
12.3. 
LABORATORY EVALUATIONS 
 
Clinical laboratory measurements, including serum chemistry and hematology, will be summarized by 
treatment group. Descriptive statistics will be presented for observed values and changes from baseline 
at each visit where parameters were scheduled to be collected per the study protocol. 
Shift tables of baseline value (high abnormal, normal, or low abnormal) to worst post-baseline value 
(high abnormal, normal, or low abnormal) will be presented by treatment group. In the case where both 
abnormal high and abnormal low values are present, the direction of the worst measurement is 
determined by whether any measurement is Panic High or Panic Low, and then by its distance from 
nearest normality limit. Laboratory measurements identified as abnormal will also be listed separately 
by subject, laboratory test, and unit. Normality interpretation (Normal, High, Low, Panic High, Panic 
Low) will be obtained from the Clinical Status assessment from the central lab (see Data Transfer Plan 
section 14  EDF-Format). Liver function tests (ALT, AST and total bilirubin) will be summarized by the 
ULN categories of 2-3 x ULN, 3-5 x ULN, 5-8 x ULN, and >8 x ULN using counts and percentages. 
Summarizations within each ULN severity category will include the highest ULN severity category per 
subject, the highest ULN severity category by visit per subject, and the number of subjects who meet 
any of the ULN severity categories by visit. For the analysis of highest ULN severity category by visit 
per subject, if a subject experiences multiple instances of the same ULN category across different study 
visits, the first visit of the highest ULN category will be reported. A plot of all subjects with at least one 
liver function test  3 x ULN will also be provided.  
12.4. 
VITAL SIGNS 
Vital sign parameter measurements will be summarized by treatment group. Descriptive statistics will 
be presented for results and change from baseline at each visit where parameters were scheduled to 
be collected.    
12.5. 
PHYSICAL EXAMINATION 
Results of the physical examination will be presented in subject data listings by subject, study visit, and 
body system.  
12.6. 
12-LEAD ECG 
Twelve-Lead ECG interval parameters including heart rate, QT interval, and QT interval corrected with 
will be summarized by treatment group. Descriptive statistics will be presented for 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 15 of 20 
observed values and changes from baseline at each visit where parameters were scheduled to be 
collected. 
Twelve-lead ECG will be cla
-by-three contingency tables will be presented to summarize 
the shift from the baseline category to the worst post-baseline category. Summary results will include 
the count and percentage of subjects within each shift category and treatment group. 
Prolonged QTcF intervals will be summarized as QTcF measurements (msec) that are >450, >480, and 
>500 at each visit where ECG is routinely collected per the clinical study protocol. Change from 
baseline categories will also be summarized for measurements that represent a change >30 or >60 
relative to the baseline value. Summary results will include the percentage of subjects within each 
category and treatment group. 
12.7. 
PREGNANCIES 
No pregnancies are expected to occur during the study. If any, these will be listed without any 
quantitative analysis. 
13. EFFICACY ANALYSES 
All efficacy analyses will be performed in the ITT Population. Primary and secondary efficacy analyses 
will also be performed on the PP Population. All efficacy analyses of ocular measurement will reflect 
data collected specific to the study eye unless otherwise specified. 
13.1. 
PRIMARY EFFICACY ANALYSIS 
The primary estimand is the mean change from baseline to Week 36 in BCVA ETDRS letters read for 
each AKST4290 group for subjects in the ITT Population. The primary analysis will consider all BCVA 
data collected regardless of the number of PRN IAI received. The null hypothesis to be tested for each 
AKST4290 treatment group is that the mean change from baseline to end of treatment, Week 36, in 
BCVA ETDRS letters read less than or equal to seven letters gained. The alternate hypothesis is that 
the mean change from baseline is at least seven letters gained within an AKST4290 treatment group.  
Within each treatment group and for the AKST4290 combined groups, a restricted maximum likelihood 
(REML)-based MMRM analysis will be performed for the change from baseline in BCVA ETDRS letters 
read. Because model convergence is questionable with this sample size and all post-baseline visits 
included, the model will include data beginning at Week 4 and collected at visits scheduled every eight 
weeks thereafter up to the Week 36 visit (i.e., weeks 4, 12, 20, 28, and 36). The model will include 
treatment group and visit as fixed effects, a treatment group by visit interaction term, subject as a 
random effect, and the baseline letters read as a covariate. An appropriate covariance structure will be 
selected prior to the interim analysis and final database lock and the Kenward Rogers method will be 
used to calculate the denominator degrees of freedom for the text of fixed effects. Within each 
AKST4290 treatment group, the mean change from baseline to Week 36 in letters read will be tested 
against the null value of seven letters gained based on one-sided alpha = 0.025. To control the Type 1 
error associated with the within-group testing of two treatment groups, the tests will be performed in 
sequence as described in Section 10.9. Within each treatment group, the least-squares mean (LSM) 
and associated 95% CI will be presented for the observed and change from baseline values. A plot of 
mean BCVA letters read, to include the corresponding AUC interval p-values (see Section 13.2.5), by 
study visit will also be provided. 
The primary endpoint will be summarized by subgroups as described in Section 10.5. Sensitivity 
analysis to assess the impact of PRN IAI on the primary endpoint is described in Section 13.4. 
13.1.1. 
Additional Analyses of the Primary Endpoint 
The primary endpoint will also be analyzed to compare each AKST4290 treatment group and the 
pooled AKST4290 groups to control through Week 12 using a REML-based MMRM model to include 
fixed effects for treatment group, categorical visit, and the treatment group by visit interaction; with the 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 16 of 20 
baseline letters read as a covariate. Estimates for the least-squares mean differences (LSMD), 95% CI 
of the LSMD, and the associated p-value to test for a difference between groups will be presented. A 
descriptive assessment of non-inferiority between the AKST4290 treatment groups and Arm 3 (control) 
for the mean change from baseline to Week 36 will be considered a secondary analysis. This 
assessment will be made by computing the two-sided 95% CI for the difference in LSMs between each 
AKST4290 group and control, and the pooled AKST4290 group and control.  
Change from Week 12 in BCVA ETDRS letters read will also be reported for each treatment group and 
for the AKST4290 combined group and will include a similar REML-based MMRM analysis as 
described for the primary endpoint; a covariate of letters read at Week 12 will be included in lieu of 
baseline letters read.  
13.2. 
SECONDARY EFFICACY ANALYSES 
Secondary endpoints will be evaluated both within treatment group through the end of treatment, Week 
36, and as a comparison of each AKST4290 group and the pooled AKST4290 groups to control 
through Week 12. Sensitivity analyses to assess the impact of PRN IAI on the secondary endpoints is 
described in Section 13.4. 
13.2.1. 
BCVA Categorical Change 
The estimand for categorical change in BCVA is the proportion of subjects who meet each BCVA 
category of interest at Week 12 or Week 36 for subjects in the ITT Population. The BCVA categories for 
assessment include 0 to 5, 6 to 10, 11 to 15 and >15 letters gained from baseline, as well as 0 to 5, 6 to 
10, 11 to 15 and >15 letters lost from baseline. 
The percent of subjects meeting each BCVA category of interest from baseline to Week 12 and Week 
36 will be summarized by treatment group, and for the pooled AKST4290 groups. Subjects with missing 
data at the Week 12 or Week 36 visit will be considered to have not achieved the BCVA category of 
interest relative to that visit. Within each group, the exact 95% CI (Clopper-Pearson) will be presented 
for the proportion of subjects with the BCVA category of interest met. The proportion of subjects who 
meet each BCVA category will be further evaluated at Week 12 and Week 36 for a difference in 
proportions between each AKST4290 treatment group and the pooled AKST4290 groups against 
control (Arm 3), 
A descriptive assessment of non-inferiority between the 
groups at each of these time points will be based on an interpretation of the CIs. 
13.2.2. 
Time to First PRN Injection/First Visit Where PRN Injection Criteria are Met 
Time to the first PRN injection will be calculated in weeks for subjects assigned to the AKST4290 
treatment groups (Arm 1 and Arm 2) as the date of first PRN injection (ie, rescue) minus the first dose 
of study drug plus one, divided by seven. Time to the first visit where PRN injection criteria are met 
starting at Week 12 will be calculated in weeks as the first date where PRN injection criteria are first 
met minus the date of first dose of study drug plus one, divided by seven. Subjects who do not 
experience the event of interest (i.e. receive a PRN injection, meet the criteria for PRN IAI) while on the 
study will be censored at their last visit completed. Kaplan-Meier estimates of the distribution of time-to-
event will be tabulated and plotted by treatment group, and for the combined AKST4290 groups. The 
tabulation will include the KM estimate of the median, 25th and 75th quartiles, and 95% CIs (if 
estimable). The number and percent of subjects with events and number and percent of subjects 
censored, including reason for censoring, will be presented. In the analysis of time to first visit where 
PRN injection criteria are met, each AKST4290 treatment group and the pooled AKST4290 groups will 
be compared to control using a log rank test.  
13.2.3. 
Median Number of Injections Received per Week 
The number of injections received per week for each subject from Baseline and Week 12 to study visits 
Week 12 (from Baseline only), Week 24 and Week 36 will be reported.  The number of injections per 
week will be standardized for their time on study by dividing the number of injections by the subject 
duration on study in weeks. This may include PRN injections or scheduled injections (Arm 3). The 
number of injections received per week from Baseline is defined as the number of IAIs received on or 
after Baseline (PRN or scheduled injections) divided by (the analysis Week visit date [or end of study 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 17 of 20 
date for those subjects who terminate early] minus the date of Baseline visit plus one, divided by 
seven). The Baseline visit is defined as the visit where the first dose of study drug is taken. If the 
subject's end of study date is later than the target visit day for the analysis visit, the subject's duration is 
set as the target day for the visit defined in the protocol schedule of events. The number of injections 
received per week from Week 12 will use a similar definition, with the reference start date as the 
 The median number of injections received per Week will be summarized using 
descriptive statistics for each treatment group and for the pooled AKST4290 groups and each 
AKST4290 treatment group and the pooled AKST4290 groups will be compared to control using a 
Wilcoxon rank-sum test 
13.2.4. 
Mean Change from Baseline in CST and Compared to Control at Week 12 
The mean change from baseline to Week 36 and mean change from Week 12 to Week 36 in CST will 
be summarized using descriptive statistics for each treatment group and for the pooled AKST4290 
groups. Treatment group comparisons will be made through Week 12 using a model similar to the 
primary endpoint. A plot of CST values, to include corresponding AUC interval p-values (see Section 
13.2.5), by study visit will also be provided. 
13.2.5. 
Mean AUC Change from Baseline in BCVA ETDRS Letters Read and CST 
Mean AUC change from baseline for BCVA ETDRS letters read and CST will be provided for study 
intervals Week 0 to 12, Week 0 to 24, Week 12 to 24, Week 0 to 36, Week 12 to 36 and Week 24 to 36 
using actual elapsed time from dosing. For AUC study interval calculations, the linear trapezoidal rule 
formula will be used: 
 
 
Treatment group comparisons for the mean AUC change will be performed using an ANCOVA model 
with a covariate for the baseline value of interest. Estimates for the least-squares mean differences 
(LSMD), 95% CI of the LSMD, and the associated p-value for treatment group comparisons will be 
presented.    
 
13.3. 
EXPLORATORY EFFICACY ANALYSES 
Exploratory efficacy analysis will include the evaluation of primary and secondary endpoints collected 
over time at all post-baseline time points through Week 40 (as available). The primary endpoint, BCVA 
ETDRS letters read will also be assessed for a study site effect; within-group tests and tests to 
compare treatment groups will be conducted using methods similar to the primary endpoint with study 
site included as a fixed effect and a treatment group by study site interaction. Low enrolling sites, 
defined as any site which enrolls  5 randomized subjects, will be pooled as a single site for the 
analysis.    
Exploratory efficacy endpoints include changes in LLVA, changes in visual field, changes in reading 
speed, changes in the NEI-VFQ-39 as well as the evaluation of mERG, total CNV area as reported by 
FA, and the SD-OCT parameters of SRF height, IRF height, RPED height, cube volume and CRT. 
Reading speed (words/min) will be calculated using the International Reading Speed Texts (iReST) or 
Radner Test method. Subjects that have reading speed assessed by Radner Test will have the results 
reported for the study eye, non-study eye and both eyes (OU). Continuous endpoints will be 
summarized using descriptive statistics by treatment group and visit. Within-group tests and tests to 
compare treatment groups will be conducted using methods similar to the primary endpoint.  
Reading speed is calculated based on the method used: 
 
iReST: Reading Speed Score (Words/Min) = 60 x (Words Read Correctly  (Words Read 
Incorrectly + Words Omitted))/Reading Time (sec) 
 
Radner Test:  


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 18 of 20 
o Using the 0.7, 0.8, 0.9 logMAR Reading Times reported on the CRF, calculate the 
Average Reading Time* 
o Reading Speed Score (Words/Min)* = 60 x (14 / Average Reading Time (sec)) 
o *Note: Average Reading Time and Reading Speed Score (Words/Min) is calculated 
separately for OD, OS and OU assessments 
 
13.4. 
SENSITIVITY EFFICACY ANALYSES 
Sensitivity analyses of the primary and secondary endpoints will be conducted to better assess the 
impact of intercurrent events on the efficacy conclusions. Here, the intercurrent events are subject 
receipt of IAI after Week 12. A distinction is made for subjects who meet the criteria for PRN injection 
after Week 12 versus those subjects who actually receive PRN IAI, since subjects in the control group 
(Arm 3) are scheduled to receive injections regardless of criteria met every four weeks beginning at 
Week 12. The sensitivity analysis will be based on the first time a subject meets the criteria for PRN IAI 
starting at Week 12, regardless of treatment group assignment. The primary and secondary efficacy 
analysis of BCVA and CST endpoints will be conducted through Week 36, without regard for whether 
subjects received PRN IAI or the number of PRN injections received. Sensitivity analyses will be 
conducted on the following: 
 
Mean change from baseline to the first time a subject meets the criteria for PRN IAI, or Week 
36/End of Treatment (EOT) for those subjects who never meet PRN injection criteria, in BCVA 
ETDRS letters read 
 
Mean change from baseline to the first time a subject meets the criteria for PRN IAI, or Week 
36/EOT for those subjects who never meet PRN injection criteria, in CST 
 
Mean change from baseline to Week 36 in ETDRS BCVA by the subset of subjects who never 
meet the criteria for PRN IAI, and those who meet the criteria at least once while on study 
 
Mean change from baseline to Week 36 in CST by the subset of subjects who never meet the 
criteria for PRN IAI, and those who meet the criteria at least once while on study 
 
Percentage of subjects with a BCVA categorical change of interest at Week 12 and Week 36 
and who never meet the criteria for PRN IAI while on study, and those subjects who met the 
PRN injection criteria at least once while on study. 
Treatment group comparison for the mean change endpoints will be performed using an ANCOVA 
model with a covariate for the baseline value of interest. Treatment group comparison of the BCVA and 
PRN IAI composite 
 
13.5. 
BIOMARKER AND AQUEOUS HUMOR ANALYSES 
Disease-related markers may include inflammatory mediators or markers of oxidative stress. 
Biomarkers will be measured in plasma samples to investigate any change in response to treatment. 
Analysis of biomarkers will be conducted by a separate vendor and are outside the scope of the 
analysis plan. 
13.6. 
PHARMACOGENOMIC ANALYSES 
Analysis of pharmacogenomics will be conducted by a separate vendor and is outside the scope of this 
analysis plan. 
14. PHARMACOKINETIC ANALYSES 
Only data from AKST4290 group will be used for pharmacokinetic analyses. 
Data handling methods outlined in study protocol section 17.5 will be followed (missing data not 
included, values below lower limit of quantification replaced with zero, parameter estimates, and 
descriptive statistics only reported when at least 2/3 data are available). 
Descriptive statistics (including mean, median and quartiles) of AKST4290 and its metabolite, M373, 
will be reported for all timepoints of pharmacokinetic sampling. 


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 19 of 20 
For each subject, the average pre-dose plasma concentration of AKST4290 in steady state will be 
calculated as geometric mean of pre-dose samples from visits 3, 4 and 5. Descriptive statistics of those 
steady state concentrations will be presented by treatment group and by sex. 
The overall mean of AKST4290 pre-dose plasma concentration is also reported along with 95% 
confidence interval. Mean pre-dose and post-dose plasma concentrations of AKST4290 and M373 will  
be provided in plots. 
 
15. CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED 
ANALYSES 
The planned analyses outlined in this SAP includes deviations from the protocol as outlined below. 
 
as:  
The secondary objectives include the time to PRN injection (Arms 1 and 2 only), time to the first visit 
where PRN injection criteria are met, median number of injections received beginning at Week 12, 
compared with control through Week 12, mean change in BCVA compared with control through Week 
12, and overall safety.  
as:  
 
Time to PRN injection (Arms 1 and 2 only).  
 
Time to first visit where PRN injection criteria are met.  
 
Median number of injections received beginning at Week 12.  
 
 
 
Mean change in CST compared with control through Week 12.  
 
Mean change in BCVA per the ETDRS testing method compared with control through Week 12.  
 
Safety as assessed by incidence and intensity of AEs. 
 
Median number of injections received will also be assessed using Baseline as a starting reference 
point, in addition to Week 12. The proportion of subjects with BCVA change will be assessed by the 
following categories: 0-5, 6-10, 11-15 and >15 letters gained or lost. Mean change from Week 12 in 
BCVA per the ETDRS testing method will also be assessed. Mean AUC change in BCVA and CST 
from Baseline to Week 36 assessing study visit intervals of Week 0 to 12, Week 0 to 24, Week 12 to 
24, Week 0 to 36, Week 12 to 36 and Week 24 to 36 will be reported. 
 
as:  
The exploratory objectives include investigation of the changes in visual field (as available), LLVA, and 
reading speed. Evaluations of mERG and OCT-A will also be performed at select sites, as available. 
Morphologic changes (CST, SRF, IRF, RPED height, and CNV) will be evaluated by SD-OCT, FP/FAF 
(FAF to be performed at select sites, as available), and FA. Biomarker, PK, and pharmacogenomic 
evaluations will be conducted on blood and plasma samples. Dose response will be investigated by 
assessing the mean change in BCVA and the number of injections by study visit. Changes in the NEI-
VFQ-39 will also be assessed. Optional aqueous humor testing will be conducted in select subjects. 
 
study as:  
 
 
Changes in visual field (as available), LLVA, and reading speed.  


Statistical Analysis Plan
Protocol number: AKST4290-205
Version: 3.0 
 
Protocol Version: 3.0 
 
Confidential 
Page 20 of 20 
 
Evaluation of mERG and OCT-A in select subjects, as available.  
 
Changes in CST, SRF, IRF, RPED height, and CNV as measured by SD-OCT, FP/FAF (FAF to 
be performed at select sites, as available), and FA.  
 
Biomarker, PK, and pharmacogenomic assessments.  
 
Dose response as assessed by mean change in BCVA and number of injections by study visit.  
 
Changes in NEI-VFQ-39 by study visit.  
 
Optional aqueous humor testing will be conducted in select subjects  
 
OCT-A is not available and will not be analyzed. Changes in CRT and cube volume will be reported in 
addition to SRF, IRF and RPED height. Total CNV area will be analyzed, as measured by FA.  
 
ibes the MMRM analysis 
to include visit as a fixed effect, patient as a random effect, and the baseline letters read as a covariate.  
 
Treatment group will be included as a fixed effect; a treatment group by visit interaction will also be 
included.  
16. LIST OF TABLES, LISTINGS, AND FIGURES 
16.1. 
TABLES 
16.2. 
LISTINGS 
16.3. 
FIGURES